Skip to main content

Jeff Lagasse

By Jeff Lagasse | 11:13 am | May 12, 2022
The proposed transaction includes Pfizer's acquisition of Biohaven's migraine drugs, including rimegepant and zavegepant.
By Jeff Lagasse | 04:24 pm | May 11, 2022
Part of the issue is that nursing shortages have reached crisis levels, made worse by the COVID-19 pandemic.
By Jeff Lagasse | 12:32 pm | May 11, 2022
The complainant alleges LHC Group failed to share pertinent information regarding financial projections and potential conflicts of interest.
By Jeff Lagasse | 04:38 pm | May 10, 2022
The pressures of the COVID-19 pandemic have hampered progress on the patient safety front, though most hospitals received passing grades.
By Jeff Lagasse | 12:13 pm | May 10, 2022
After the waiver, the share of patients with at least one outpatient telehealth visit climbed to about 10%.
By Jeff Lagasse | 04:50 pm | May 09, 2022
Rising case counts among children complicate efforts to reduce the burden on the American healthcare system.
By Jeff Lagasse | 12:22 pm | May 09, 2022
A surge in COVID-19 cases led to a substantial increase in the demand for related care and testing, adding to expenses, Kaiser says.
By Jeff Lagasse | 05:02 pm | May 06, 2022
Centene framed the moves as the next steps in its ongoing portfolio review as it exits the pharmacy benefit management space.
By Jeff Lagasse | 01:06 pm | May 06, 2022
Cigna's underlying strategy is to capture more of the oncology care market by creating a more comprehensive framework.
By Jeff Lagasse | 05:26 pm | May 05, 2022
Twenty-five percent of primary care physicians provided 86% of the care, and 25% of specialists, on average, provided 75% of the care.